Balanced news tone
News Sentiment
CSBR sentiment intelligence
Champions Oncology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+5.3% over one week, -3.0% over four weeks, trend inactive, and near fair-value range.
Champions Oncology to announce Q4 and FY26 results on July 27
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
CSBR - Champions Oncology Inc Stock Price and Quote
This article provides a detailed overview of Champions Oncology Inc (CSBR) stock, including its latest price, financial metrics, analyst ratings, and recent news and events. It lists key financial data such as market cap, income, sales, and various ratios, alongside insider owner
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 Jun 2026 11:09
- Source
- Finviz
Champions Oncology Inc. (CSBR) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Edges Higher - Guidance Downgrade Alert
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 31 May 2026 07:00
- Source
- dars.gov.et
Champions Oncology (CSBR) Gains 1.59% as Stock Approaches Key Resistance Level - Ending Diagonal
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 May 2026 07:00
- Source
- dars.gov.et
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Rob Brainin appointed CEO of Champions Oncology
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jul 2025 07:00
- Source
- The Cancer Letter
BGI Americas partners with Champions Oncology to offer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2021 07:00
- Source
- GlobeNewswire
Champions Oncology Stock Price Forecast. Should You Buy CSBR?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 04 Dec 2020 08:21
- Source
- StockInvest.us
Champions Oncology (CSBR) Earnings Date and Reports 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Jun 2018 18:02
- Source
- MarketBeat
CSBR Stock Price and Chart — NASDAQ:CSBR
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2017 03:27
- Source
- TradingView